V. Pöschel

Rituximab for the treatment of diffuse large B-cell lymphomas

M. Pfreundschuh, G. Held, V. Pöschel, 2006, Expert review of anticancer therapy.

Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL.

A. Rosenwald, M. Ziepert, W. Klapper, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

A 70% cut-off for MYC protein expression in diffuse large B cell lymphoma identifies a high-risk group of patients.

A. Rosenwald, M. Ziepert, N. Schmitz, 2020, Haematologica.

Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma.

C. Rübe, M. Ziepert, N. Schmitz, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopenia.

N. Schmitz, M. Pfreundschuh, M. Loeffler, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Identification of the atypically modified autoantigen Ars2 as the target of B-cell receptors from activated B-cell-type diffuse large B-cell lymphoma

A. Rosenwald, W. Klapper, A. Mottok, 2020, Haematologica.

Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients

C. Rübe, M. Ziepert, N. Schmitz, 2017, British journal of haematology.

Improved Outcome of Elderly Poor-Prognosis DLBCL Patients with 6xCHOP-14 and 8 Applications of Rituximab (R) Given Over An Extended Period: Results of the SMARTE-R-CHOP-14 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)

M. Pfreundschuh, M. Reiser, S. Zeynalova, 2011 .

Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL.

A. Rosenwald, M. Ziepert, W. Klapper, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.